AR080375A1 - Procedimiento para la preparacion de 2-(cicloheximetil)-n-{2-[(2s)-1-metilpirrolidin-2-il] etil}-1,2,3,4-tetrahidroisoquinolina- 7-sulfonamida - Google Patents

Procedimiento para la preparacion de 2-(cicloheximetil)-n-{2-[(2s)-1-metilpirrolidin-2-il] etil}-1,2,3,4-tetrahidroisoquinolina- 7-sulfonamida

Info

Publication number
AR080375A1
AR080375A1 ARP110100673A ARP110100673A AR080375A1 AR 080375 A1 AR080375 A1 AR 080375A1 AR P110100673 A ARP110100673 A AR P110100673A AR P110100673 A ARP110100673 A AR P110100673A AR 080375 A1 AR080375 A1 AR 080375A1
Authority
AR
Argentina
Prior art keywords
tetrahydroisoquinoline
cyclohexylmethyl
salt
sulfonamide
methylpyrrolidin
Prior art date
Application number
ARP110100673A
Other languages
English (en)
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44012569&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR080375(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of AR080375A1 publication Critical patent/AR080375A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A61P5/20—Drugs for disorders of the endocrine system of the parathyroid hormones for decreasing, blocking or antagonising the activity of PTH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
    • C07C51/41—Preparation of salts of carboxylic acids
    • C07C51/412—Preparation of salts of carboxylic acids by conversion of the acids, their salts, esters or anhydrides with the same carboxylic acid part
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C07D217/04—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

Abstract

Reivindicacion 1: Un procedimiento para preparar 2-(ciclohexilmetil)-N-{2-[(2S)-1-metilpirrolidin-2-il]etil}-1,2,3,4-tetrahidroisoquinolina-7-sulfonamida, o una sal farmacéuticamente aceptable de la misma o un solvato o hidrato de una sal farmacéuticamente aceptable que comprende: a) la aminacion reductora de 1,2,3,4-tetrahidroisoquinolina, o una de sus sales, con ciclohexanocarboxaldehído para dar 2-ciclohexilmetil-1,2,3,4-tetrahidroisoquinolina, o una de sus sales; b) hacer reaccionar 2-ciclohexilmetil-1,2,3.4-tetrahidroisoquinolina, o una de sus sales, con un exceso de ácido clorosulfonico para dar la sal HX del cloruro de 2-ciclohexilmetil-1,2,3,4-tetrahidroisoquinolina-7-sulfonilo, y opcionalmente recristalizar la sal HX del cloruro de 2-ciclohexilmetil-1,2,3,4-tetrahidroisoquinolina-7-sulfonilo; c) acoplar la sal HX del cloruro de 2-ciclohexilmetil-1,2,3,4-tetrahidroisoquinolina-7-sulfonilo con (-)-2-(2-aminoetil)-1-metilpirrolidina para formar 2-(ciclohexilmetil)-N-{2-[(2S)-1-metilpirrolidin-2-il]etil}-1,2,3,4-tetrahidroisoquinolina-7-sulfonamida; d) hacer reaccionar opcionalmente 2-(ciclohexilmetil)-N-{2-[(2S)-1-metilpirrolidin-2-il]etil}-1,2,3,4-tetrahidroisoquinolina-7-sulfonamida con una cantidad estequiométrica o un exceso de un ácido formador de sal en un disolvente para formar una sal o un hidrato o solvato de la misma; y e) recristalizar opcionalmente el producto de la etapa d).
ARP110100673A 2010-03-05 2011-03-03 Procedimiento para la preparacion de 2-(cicloheximetil)-n-{2-[(2s)-1-metilpirrolidin-2-il] etil}-1,2,3,4-tetrahidroisoquinolina- 7-sulfonamida AR080375A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US31106910P 2010-03-05 2010-03-05
FR1059750 2010-11-25

Publications (1)

Publication Number Publication Date
AR080375A1 true AR080375A1 (es) 2012-04-04

Family

ID=44012569

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP110100673A AR080375A1 (es) 2010-03-05 2011-03-03 Procedimiento para la preparacion de 2-(cicloheximetil)-n-{2-[(2s)-1-metilpirrolidin-2-il] etil}-1,2,3,4-tetrahidroisoquinolina- 7-sulfonamida
ARP110100672A AR080374A1 (es) 2010-03-05 2011-03-03 Procedimiento para la preparcion de 2-(ciclohexilmetil)-n-(2-((2s)-1-metilpirrolidin-2-il) etil)- 1,2,3,4-tetrahidroisoquinolin-7- sulfonamida

Family Applications After (1)

Application Number Title Priority Date Filing Date
ARP110100672A AR080374A1 (es) 2010-03-05 2011-03-03 Procedimiento para la preparcion de 2-(ciclohexilmetil)-n-(2-((2s)-1-metilpirrolidin-2-il) etil)- 1,2,3,4-tetrahidroisoquinolin-7- sulfonamida

Country Status (28)

Country Link
US (2) US8748615B2 (es)
EP (2) EP2556064B1 (es)
JP (2) JP2013521308A (es)
KR (2) KR101783679B1 (es)
CN (2) CN103068815A (es)
AR (2) AR080375A1 (es)
AU (2) AU2011222588B2 (es)
BR (2) BR112012022356A2 (es)
CA (2) CA2789669A1 (es)
CL (2) CL2012002452A1 (es)
CO (2) CO6630099A2 (es)
CR (1) CR20120467A (es)
DO (1) DOP2012000228A (es)
EC (1) ECSP12012207A (es)
GT (1) GT201200228A (es)
IL (2) IL221341A (es)
MA (2) MA34144B1 (es)
MX (2) MX2012009413A (es)
NZ (2) NZ601498A (es)
PE (1) PE20130007A1 (es)
PH (2) PH12012501641A1 (es)
RU (2) RU2012142310A (es)
SG (2) SG182576A1 (es)
TN (1) TN2012000361A1 (es)
TW (2) TW201144285A (es)
UY (2) UY33262A (es)
WO (2) WO2011109680A2 (es)
ZA (1) ZA201205311B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR080375A1 (es) 2010-03-05 2012-04-04 Sanofi Aventis Procedimiento para la preparacion de 2-(cicloheximetil)-n-{2-[(2s)-1-metilpirrolidin-2-il] etil}-1,2,3,4-tetrahidroisoquinolina- 7-sulfonamida
CN102816101A (zh) * 2012-08-21 2012-12-12 江苏恒祥化工有限责任公司 一种(s)-n-甲基-2氯乙基吡咯烷的合成方法
EP3043799A1 (en) * 2013-09-09 2016-07-20 Sanofi An h3 receptor antagonist combined with a cholinesterase inhibitor for use in the treatment of alzheimer's disease
EP3692041A1 (en) * 2017-10-04 2020-08-12 Celgene Corporation Processes for the preparation of cis-4 [2-{(3s.4r)-3-fluorooxan-4-yl]amino)-8-(2,4,6-trichloroanilino)-9h-purin-9-yl]-1-methylcyclohexane-1-carboxamide

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4228170A (en) 1979-08-30 1980-10-14 Smithkline Corporation 7- and/or 8-Sulfur substituted 1,2,3,4-tetrahydroisoquinoline compounds
US4315935A (en) * 1980-04-14 1982-02-16 Smithkline Corporation N,N'-Bis[substituted-1,2,3,4-tetrahydroisoquinolinolyl]disulfonylimides and antiallergic compositions and method of use
GB8717374D0 (en) 1987-07-22 1987-08-26 Smith Kline French Lab Pharmaceutically active compounds
US4857301A (en) 1987-09-25 1989-08-15 Schering Corporation Sulfonamide compounds, compositions and method of use
JPH08511538A (ja) 1993-06-09 1996-12-03 スミスクライン・ビーチャム・コーポレイション 二環式フィブリノゲン拮抗物質
GB9322976D0 (en) 1993-11-08 1994-01-05 Pfizer Ltd Therapeutic agents
GB9709303D0 (en) * 1997-05-09 1997-06-25 Smithkline Beecham Plc Compounds
SK15072000A3 (sk) 1998-04-10 2001-08-06 Japan Tobacco Inc. Amidové zlúčeniny
GB9816984D0 (en) 1998-08-05 1998-09-30 Smithkline Beecham Plc Novel compounds
CA2347095A1 (en) 1998-10-16 2000-04-27 Takeda Chemical Industries, Ltd. Nitrogen-containing condensed heterocyclic derivatives, their production and agent
PL350884A1 (en) 1999-04-01 2003-02-10 Pfizer Prod Inc Aminopyrimidines as sorbitol dehydrogenase inhibitors
GB9912410D0 (en) 1999-05-28 1999-07-28 Pfizer Ltd Compounds useful in therapy
PE20010628A1 (es) 1999-10-01 2001-06-18 Takeda Chemical Industries Ltd Compuestos de amina ciclica, su produccion y su uso
MXPA02005528A (es) 1999-12-03 2002-09-02 Kyoto Pharma Ind Compuestos heterociclicos sus sales y uso medicinal.
FR2804429B1 (fr) 2000-01-31 2003-05-09 Adir Nouveaux derives de 4-sulfonamides piperidine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR2807434B1 (fr) 2000-04-05 2002-10-18 Hoechst Marion Roussel Inc Nouveaux derives de la 1,2,3,4-tetrahydroisoquinoleine, leur procede de preparation et leur application comme fongicides
KR100823908B1 (ko) 2000-10-20 2008-04-21 바이오비트럼 에이비(피유비엘) 2-, 3-, 4-, 또는 5-치환-ｎ1-(벤젠술포닐)인돌 및 이의치료 용도
JP2004517058A (ja) * 2000-10-30 2004-06-10 ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー アミノアルキルピロリジンセロトニン受容体リガンドおよび組成物、その医薬的使用およびその合成方法
JP2004532834A (ja) 2001-03-23 2004-10-28 イーライ・リリー・アンド・カンパニー ヒスタミンｈ３受容体アンタゴニストである非イミダゾール系アリールアルキルアミン化合物、その製造および治療的使用
US6949553B2 (en) * 2001-06-18 2005-09-27 Maruha Corporation Aliphatic compounds, their synthesis method, and utilization of the same
US20050043304A1 (en) 2001-08-01 2005-02-24 Yutaka Kato Novel amine derivative having human beta-tryptase inhibitory activity and drugs containing the same
US6677349B1 (en) 2001-12-21 2004-01-13 3M Innovative Properties Company Sulfonamide and sulfamide substituted imidazoquinolines
WO2003055848A2 (en) 2001-12-26 2003-07-10 Bayer Healthcare Ag Urea derivatives as vr1- antagonists
US6867224B2 (en) 2002-03-07 2005-03-15 Warner-Lambert Company Compounds that modulate PPAR activity and methods of preparation
CA2521625A1 (en) 2003-04-17 2004-11-04 Merck & Co., Inc. Heterocyclic cyclopentyl tetrahydroisoquinoline and tetrahydropyridopyridine modulators of chemokine receptor activity
FR2857695B1 (fr) 2003-07-15 2007-04-20 Saint Gobain Ct Recherches Bloc pour la filtration de particules contenues dans les gaz d'echappement d'un moteur a combustion interne
JP2007519633A (ja) 2004-01-02 2007-07-19 メルク　エンド　カムパニー　インコーポレーテッド アルキルアミノ、アリールアミノおよびスルホンアミドシクロペンチルアミド系のケモカイン受容体活性調節剤
EP1732552A4 (en) 2004-01-20 2007-12-19 Merck & Co Inc 2,6-DISUBSTITUTED PIPERIDINES AS MODULATORS OF CHEMOKIN RECEPTOR ACTIVITY
US7557124B2 (en) 2004-04-26 2009-07-07 Merck & Co., Inc. Tetrahydropyranyl cyclopentyl tetrahydropyridopyridine modulators of chemokine receptor activity
EP1742919A4 (en) 2004-04-26 2010-04-28 Merck Sharp & Dohme TETRAHYDROPYRANYL-CYCLOPENTYL-1-SUBSTITUTED AND 1,1-DISUBSTITUTED TETRAHYDROISOCHINOLINE MODULATORS OF CHEMOKIN RECEPTOR ACTIVITY
CN1950085A (zh) 2004-05-11 2007-04-18 因赛特公司 作为趋化因子受体调节剂的3－(4－杂芳基环己基氨基)环戊烷羧酰胺
FR2870846B1 (fr) 2004-05-25 2006-08-04 Sanofi Synthelabo Derives de tetrahydroisoquinolylsulfonamides, leur preparation et leur utilisation en therapeutique
US7470722B2 (en) 2004-06-10 2008-12-30 Kalypsys, Inc. Multicyclic sulfonamide compounds as inhibitors of histone deacetylase for the treatment of disease
EP1630158A1 (en) 2004-08-18 2006-03-01 Laboratorios Del Dr. Esteve, S.A. 5-HT7 receptor antagonists
ES2257168B1 (es) 2004-08-18 2007-06-01 Laboratorios Del Dr Esteve, S.A. Ligandos del receptor 5-ht7.
EP2311827A1 (en) 2004-08-28 2011-04-20 AstraZeneca AB Thiopyrimidine derivative, useful as an intermediate for chemokine receptor modulators.
SE0403086D0 (sv) 2004-12-17 2004-12-17 Astrazeneca Ab Compounds
WO2006068826A2 (en) 2004-12-21 2006-06-29 Smithkline Beecham Corporation 2-pyrimidinyl pyrazolopyridine erbb kinase inhibitors
JP2008525419A (ja) 2004-12-22 2008-07-17 ファイザー・リミテッド Ｈｉｖ−１逆転写酵素の非ヌクレオシド阻害剤
BRPI0607241A2 (pt) 2005-01-26 2009-08-25 Hoffmann La Roche derivados de fenil metanona e o uso dos mesmos como inibidores do transportador de glicina 1
DE102005015040A1 (de) 2005-03-31 2006-10-05 Sanofi-Aventis Deutschland Gmbh Substituierte Tetrahydroisochinoline als MMP-Inhibitoren, Verfahren zu ihrer Herstellung und ihre Verwendung als Medikament
AR053845A1 (es) 2005-04-15 2007-05-23 Tibotec Pharm Ltd 5-tiazolilmetil[(1s,2r)-3-[[(2-amino-6-benzoxazolil)sulfonil)](2-metilpropil)amino]-2-hidroxi-1-(fenilmetil)propil]carbamato como mejorador de farmacos metabolizados por el citocromo p450
CN101218235A (zh) 2005-05-10 2008-07-09 沃泰克斯药物股份有限公司 作为离子通道调控剂的二环衍生物
EP1911747A1 (en) 2006-10-11 2008-04-16 Laboratorios del Dr. Esteve S.A. Sulfonamide substituted pyrazoline compounds, their preparation and use as CB1 modulators
WO2008136378A1 (ja) 2007-04-27 2008-11-13 Toyama Chemical Co., Ltd. 新規なスルホンアミド誘導体またはその塩
CN102036952A (zh) 2008-04-16 2011-04-27 比奥里波克斯公司 用作药物的双芳基化合物
WO2010127272A2 (en) 2009-04-30 2010-11-04 Concert Pharmaceuticals, Inc. Hydroxyethylamino sulfonamide derivatives
NZ597219A (en) 2009-06-26 2013-05-31 Sanofi Sa Novel fumarate salts of a histamine h3 receptor antagonist
AR080375A1 (es) 2010-03-05 2012-04-04 Sanofi Aventis Procedimiento para la preparacion de 2-(cicloheximetil)-n-{2-[(2s)-1-metilpirrolidin-2-il] etil}-1,2,3,4-tetrahidroisoquinolina- 7-sulfonamida

Also Published As

Publication number Publication date
MA34144B1 (fr) 2013-04-03
SG182576A1 (en) 2012-08-30
WO2011109680A3 (en) 2012-12-20
MX2012009413A (es) 2012-09-07
US8779145B2 (en) 2014-07-15
KR20130038186A (ko) 2013-04-17
CN103221394A (zh) 2013-07-24
CO6630099A2 (es) 2013-03-01
CA2787427A1 (en) 2011-09-09
RU2012142338A (ru) 2014-04-10
PH12012501641A1 (en) 2012-10-22
TW201144285A (en) 2011-12-16
CL2012002451A1 (es) 2012-11-30
WO2011109675A2 (en) 2011-09-09
CN103068815A (zh) 2013-04-24
AR080374A1 (es) 2012-04-04
ZA201205311B (en) 2013-03-27
EP2556064A2 (en) 2013-02-13
GT201200228A (es) 2013-11-21
UY33263A (es) 2011-09-30
MA34142B1 (fr) 2013-04-03
IL221339A0 (en) 2012-10-31
CL2012002452A1 (es) 2012-11-30
DOP2012000228A (es) 2013-01-15
IL221341A0 (en) 2012-10-31
EP2542530A2 (en) 2013-01-09
PH12012501499A1 (en) 2018-02-07
CA2789669A1 (en) 2011-09-09
SG183256A1 (en) 2012-09-27
NZ601498A (en) 2014-12-24
US8748615B2 (en) 2014-06-10
US20130123302A1 (en) 2013-05-16
CO6630129A2 (es) 2013-03-01
WO2011109680A2 (en) 2011-09-09
JP2013521309A (ja) 2013-06-10
US20130137718A1 (en) 2013-05-30
MX2012008422A (es) 2012-08-15
BR112012022356A2 (pt) 2016-08-30
RU2012142310A (ru) 2014-04-10
NZ602009A (en) 2015-01-30
ECSP12012207A (es) 2013-03-28
CA2787427C (en) 2017-10-10
BR112012022234A2 (pt) 2015-12-15
AU2011222588A1 (en) 2012-08-23
JP5927126B2 (ja) 2016-05-25
IL221341A (en) 2014-05-28
KR101783679B1 (ko) 2017-10-10
TN2012000361A1 (en) 2014-01-30
TW201144284A (en) 2011-12-16
AU2011223560A1 (en) 2012-09-13
KR20130047685A (ko) 2013-05-08
CR20120467A (es) 2012-10-05
PE20130007A1 (es) 2013-02-01
UY33262A (es) 2011-09-30
AU2011222588B2 (en) 2016-09-08
EP2556064B1 (en) 2014-10-15
WO2011109675A3 (en) 2012-11-22
JP2013521308A (ja) 2013-06-10

Similar Documents

Publication Publication Date Title
MX344580B (es) Combinacion de panobinostat y ruxolitinib en el tratamiento del cancer tal como una neoplasia mieloproliferativa.
MY196276A (en) Isoindole Compounds
AR051754A1 (es) Metodos para preparar compuestos de indazol
ES2541857T3 (es) Procesos para preparar ciclopropilamidas e intermedios asociados con estas
AR090566A1 (es) Proceso para la produccion de inhibidores de crr
AR080374A1 (es) Procedimiento para la preparcion de 2-(ciclohexilmetil)-n-(2-((2s)-1-metilpirrolidin-2-il) etil)- 1,2,3,4-tetrahidroisoquinolin-7- sulfonamida
AR086803A1 (es) Derivados de oxazetidinas, composiciones farmaceuticas y cosmeticas que los contienen y uso de los mismos para tratar enfermedades dermatologicas fundamentalmente, y del aparato respiratorio, digestivo y cardiovascular, entre otras
AR100095A1 (es) Formas sólidas del ácido {[(2r,3s,4r,5s)-4-(4-cloro-2-fluoro-fenil)-3-(3-cloro-2-fluoro-fenil)-4-ciano-5-(2,2-dimetil-propil)-pirrolidin-2-carbonil]-amino}-3-metoxi-benzoico
ECSP12012329A (es) Nueva asociación entre la 4-{3-[cis-hexahidrociclopenta[c]pirrol-2(1h)-il]propoxi}benzamida y un antagonista de los receptores nmda y las composiciones farmacéuticas que la contienen
EA201301136A3 (ru) Новый способ синтеза (2e)-3-(3,4-диметоксифенил)проп-2-еннитрила, применение в синтезе ивабрадина и его фармацевтически приемлемых кислотно-аддитивных солей
PY1420162A (es) Procedimiento de síntesis del 3,4-dimetoxibiciclo (4.2.0) octa-1,3,5-trien-7- carbonitrilo, y aplicación a la síntesis de la ivabradina y de sus sales de adición a un ácido
MX2015006806A (es) Procedimiento para preparar 4-(ciclopropilmetoxi)-n-(3,5-dicloro-1 -oxido-4-piridil)-5-metoxipiridina-2-carboxamida.
UY35503A (es) Titulo: procedimiento de síntesis de derivados de la 7,8-dimetoxi-1,3 -dihidro-2h-3- benzazepin -2- ona y aplicación a la síntesis de la ivabradina
NI201200127A (es) Procedimiento para la preparación de 2 - ( ciclohexilmetil ) - n - { 2 - [ (2s) - 1 - metilpirrolidin - 2 - il ] etil } - 1, 2, 3, 4 - tetrahidroisoquinolin - 7 - sulfonamida.
TH125698A (th) กระบวนการสำหรับการเตรียม 2-(ไซโคลเฮกซิลเมทิล)-n-{2-[2s)-1-เมทิลไพโพรลิดิน-2-อิล]เอทิล}-1,2,3,4-เตตระไฮโดรไอโซควิโนลีน-7-ซัลโฟนาไมด์
CN302305952S (zh) 双头夹具（a01）
CN302305953S (zh) 双头夹具（a02）
TH134765A (th) เกลือฟูมาเรตใหม่ของแอนตาโกนิสต์ที่จับกับตัวรับฮิสตามีนชนิดเอช3
AR108197A1 (es) Proceso para la elaboración de idalopirdina mediante la hidrogenación de una imina
CN302236049S (zh) 手提包

Legal Events

Date Code Title Description
FB Suspension of granting procedure